安宫牛黄丸对脓毒症大鼠JAK/STAT通路的干预作用
摘要
目的：在成功复制脓毒症动物模型基础之上,从分子细胞层面探讨脓毒症的发病机制,并采用安宫牛黄丸进行干预,观察安宫牛黄丸对脓毒症大鼠的保护作用,并在此基础上观察安宫牛黄丸对脓毒症早期炎症介质TNF-α、晚期炎症介质HMGB-1的mRNA表达的影响以及对JAK/STAT通路活化的影响,从分子水平探索安宫牛黄丸治疗脓毒症的机制和深层次靶点,为中医药治疗脓毒症的机理研究能够深入到分子水平、为丰富和发展中医温病学治法理论的科学内涵、阐述中医名方安宫牛黄丸治疗温热病危重症候(脓毒症)的现代药理机制、为进一步探索中西医结合治疗高发病率、高病死率重大疾病脓毒症的方案打下理论基础。
方法：采用盲肠结扎穿孔法(CLP)复制脓毒症动物模型。SPF级大鼠90只,雌雄各半,随机分为5组,(1)正常对照组(n=10),麻醉后取血,处死取材待测；(2)模型组(n=20),于CLP前0.5h,CLP后6h,以10ml／kg体重灌胃蒸馏水,并于术后24h取血、处死取材待测；(3)安宫牛黄丸低、中、高剂量干预组各20只(n=60),于CLP前0.5h,CLP后6h,分别以1.0g／kg、2.0g／kg、3.0g／kg体重灌胃给药,并于术后24h取血、处死取材待测。同时观察各组动物24小时内死亡率及一般表现；动物尸体解剖腹腔感染程度；检测术后第6h、12h、24h动物肛温；血分析仪检测术后24小时动物白细胞计数；全自动生化分析仪测定血清ALT、AST、BUN、Crea、TB水平；酶学分光光度法测定肺组织髓过氧化物酶(MPO)含量；显色基质鲎试剂测定血浆内毒素含量；半定量RT-PCR法检测肝脏、肺脏、肾脏STAT1、STAT3、TNF-α、HMGB-1 mRNA的表达；EMSA法检测肝脏、肺脏STAT1、STAT3 DNA结合活性。
结果：采用CLP法复制脓毒症动物模型,动物术后6小时后病态逐渐明显,并开始出现死亡,动物活动减少,不再合群取暖,嗜睡,竖毛,不饮水,有的出现呼吸急促,脓尿,腹泻,眼角渗出物等,24小时的累积死亡率达到了55%；从动物尸检发现腹腔感染程度比较严重；模型动物一直处于一个低温状态(中心体温<36℃)并出现了白细胞减少症(外周血白细胞计数或<4×109／L),并同时伴有主要脏器的严重损害(血清ALT、AST、TB水平显著高于正常对照组动物、肺脏MPO活性显著高于正常对照组)；脓毒症动物血浆内毒素水平要显著高于正常对照组；脓毒症大鼠各主要脏器STAT1、STAT3 DNA活性显著升高,JAK/STAT通路高度活化,同时早期炎症介质TNF-α、晚期炎症介质HMGB-1的mRNA表达显著上调。
安宫牛黄丸能够改善脓毒症大鼠的一般表现,显著降低脓毒症大鼠的死亡率,提高脓毒症休克时大鼠的体温,提高脓毒症大鼠的白细胞计数,安宫牛黄丸具有降低脓毒症大鼠血清ALT、AST水平的趋势,能够显著降低脓毒症大鼠血清TB水平,降低脓毒症大鼠肺脏MPO活性,降低脓毒症大鼠血浆内毒素含量；安宫牛黄丸能够显著下调JAK/STAT通路中STAT1和STAT3的mRNA表达,能够显著减弱STATs RNA的结合活性,显著降低JAK/STAT通路的活化程度,同时还能显著下调TNF-α和HMG-1mRNA的表达。
结论：采用CLP法能够成功复制脓毒症大鼠模型；大鼠脓毒症的发病机制可能与JAK/STAT通路高度活化以及由此通路激活的早期TNF-α、晚期炎症介质HMGB-1等炎症介质释放有关,并由此而导致了炎症反应失控,最终可能引起脏器的损害,引发MODS、脓毒症休克等。安宫牛黄丸能够降低脓毒症大鼠模型的死亡率,提高脓毒症休克时大鼠的体温,提高脓毒症大鼠的白细胞计数,对脓毒症大鼠整体有较好的保护作用。同时,安宫牛黄丸能够具有降低脓毒症大鼠血清ALT、AST水平的趋势,能够显著降低脓毒症大鼠血清TB水平,降低脓毒症大鼠肺脏MPO活性、血浆内毒素含量,对脓毒症大鼠主要脏器功能有明显的改善作用,这可能是安宫牛黄丸治疗脓毒症的机制之一。
安宫牛黄丸能够显著下调脓毒症大鼠肝脏、肺脏、肾脏等主要脏器中早期炎症介质TNF-α和晚期炎症介质HMGB-1 mRNA表达；能够显著下调脓毒症大鼠肝脏、肺脏、肾脏等主要脏器中STAT1、STAT3 mRNA表达；还能显著降低JAK/STAT通路中STAT1和STAT3 DNA结合活性,降低JAK/STAT通路的活化程度。这从分子水平进一步阐明了安宫牛黄丸治疗脓毒症的作用机制,为安宫牛黄丸在危重病急救领域中的应用提供了理论基础。
Objective:based on successful replication of sepsis animals, the paper studies on the pathogenesis of sepsis from the level of molecular cell. Using the intervene treat of Angong Niu Huang Wan, the paper will observes how the pill protects the septic rats. On the basis of that, it also will check the pills'mRNA expression of early sepsis inflammatory media TNF-aand later media HMGB-1, also its effect of Janus kinase/signal transducer and activators of transcription (JAK/STAT). The pape r will offer the theoretical foundation for the application of Angong Niu Huang Wa n in injury severity from exploring the mechanism of how Angong Niu Huang Wan treating the sepsis on the basis of molecular mechanism, and deep level target.
Methods:adopting CLP to replicate the sepsis animal model; 90 SPF rats, hal f male and half female, divided into five groups, (1) the control (n=10), get the blo od after anesthesia then euthanize them for the test; (2) the model (n=20), get the blood 24h later after treating the rats with distilled water (10ml/kg) 0.5h before CL P and 6h after CLP, then euthanize them for the test; (3) Angong Niu Huang Wan low, middle and high, each 20 rats, get the blood 24 hours after gastric perfusion (1.0g/kg,2.0g/kg,3.0g/kg),0.5h before CLP and 6h after CLP, then euthanize them for the test; observe each groups and check the death rate and normal behaviors d uring the 24h; the degree of animal autopsy intraperitoneal infection; the rats rectal temperatures 6h,12h and 24h after operation; the WBC of the rats 24h after operati on measured by blood analyzer; the ALT, AST, BUN, Crea, TB levels of the Seru m measured by automatic biochemistry analyzer; the MPO content in the lung meas ured by enzymatic determination; the toxin content in the plasma by limulus polyph emus; the expression of STAT1, STAT3, TNF-αand HMGB-1 of liver, lung and kidney measured by semi-quantitative RT-PCR; the DNA binding activity of STAT1 and STAT2 measured by EMSA.
Results:based on replication of sepsis animal models by CLP, the ill conditio ns of the rats gradually increased and some rats would even die; the activities of ra ts were induced and they no longer gather together to keep warm; they has the feat ures of sleepiness with pio-erection and do not drink water; some rats even suffer t he shortness of breath, pyuria, diarrhea and eye exudate. The cumulative rate of dea th reaches 55% in 24h. Post mortem examination reveals the serious degree of intra peritoneal infection; the models'body temperatures keep in a low condition (core te mperature less then 36℃), get leukopenia (WBC maybe less than 4×109/L) and the ir main organs are seriously damaged (ALT, AST and TB levels of serum and lung MPO activity are obviously higher than the control group); the toxin level in the s epsis rats'serum is very higher than the control group; the DNA activity of STAT1 and STAT 3 of the sepsis rats'main organs also rises obviously, JAK/STAT is al so highly activated in the pathway and meanwhile, the expression of early inflamma tory media TNF-αand later media HMGB-1 is also highly raised.
Angong Niu Huang Wan can improve the normal behaviros of the sepsis rat s, obviouly reduce their death rate, raise their tempeatures during their shock and in crease their WBC count. The pills can lower the ALT and AST levels in the sepsis rats'serum, higly decreased their TB level in the serum, their lungs'MPO activity and the toxin content in their plasma. The pills can reduce JAK obviously. STAT1 and STAT3's mRNA expression in the STAT activation pathway can reduce STAT s'RNA bending activity, the pathway's activation degree of JAK/STAT and meanw hile the Mrna expression of TNF-αand HMGB-1.
Conclusion:the CLP method can successfully replicate the sepsis rate models; the pathogenesis of the septic rats might be related to the higher pathway activatio n of JAK/STAT and the release of early inflammatory media TNF-αand later med ia HMGB-1 caused by the activatio pathway so as to cause the inflammatory effect s out of control and finally lead to the organs damage, MODS and septic shock. A ngong Niu Huang Wan can well protect the sepsis. The possible molecular mechani sms treatment of the pills for sepsis is to reduce the STAT1 and STAT3 expression in the JAK/STAT activation pathway so as to reduce the JAK and STAT's activati on pathway degree, thus reduce the express of related cytokine such as TNF-α, H MGB-1, from JAK/STAT activation pathway, regulate the inflammatory infection tha t is out of control and reduce the inflection damage to organs so as to protect orga nism.
方法：采用盲肠结扎穿孔法(CLP)复制脓毒症动物模型。SPF级大鼠90只,雌雄各半,随机分为5组,(1)正常对照组(n=10),麻醉后取血,处死取材待测；(2)模型组(n=20),于CLP前0.5h,CLP后6h,以10ml／kg体重灌胃蒸馏水,并于术后24h取血、处死取材待测；(3)安宫牛黄丸低、中、高剂量干预组各20只(n=60),于CLP前0.5h,CLP后6h,分别以1.0g／kg、2.0g／kg、3.0g／kg体重灌胃给药,并于术后24h取血、处死取材待测。同时观察各组动物24小时内死亡率及一般表现；动物尸体解剖腹腔感染程度；检测术后第6h、12h、24h动物肛温；血分析仪检测术后24小时动物白细胞计数；全自动生化分析仪测定血清ALT、AST、BUN、Crea、TB水平；酶学分光光度法测定肺组织髓过氧化物酶(MPO)含量；显色基质鲎试剂测定血浆内毒素含量；半定量RT-PCR法检测肝脏、肺脏、肾脏STAT1、STAT3、TNF-α、HMGB-1 mRNA的表达；EMSA法检测肝脏、肺脏STAT1、STAT3 DNA结合活性。
结果：采用CLP法复制脓毒症动物模型,动物术后6小时后病态逐渐明显,并开始出现死亡,动物活动减少,不再合群取暖,嗜睡,竖毛,不饮水,有的出现呼吸急促,脓尿,腹泻,眼角渗出物等,24小时的累积死亡率达到了55%；从动物尸检发现腹腔感染程度比较严重；模型动物一直处于一个低温状态(中心体温<36℃)并出现了白细胞减少症(外周血白细胞计数或<4×109／L),并同时伴有主要脏器的严重损害(血清ALT、AST、TB水平显著高于正常对照组动物、肺脏MPO活性显著高于正常对照组)；脓毒症动物血浆内毒素水平要显著高于正常对照组；脓毒症大鼠各主要脏器STAT1、STAT3 DNA活性显著升高,JAK/STAT通路高度活化,同时早期炎症介质TNF-α、晚期炎症介质HMGB-1的mRNA表达显著上调。
安宫牛黄丸能够改善脓毒症大鼠的一般表现,显著降低脓毒症大鼠的死亡率,提高脓毒症休克时大鼠的体温,提高脓毒症大鼠的白细胞计数,安宫牛黄丸具有降低脓毒症大鼠血清ALT、AST水平的趋势,能够显著降低脓毒症大鼠血清TB水平,降低脓毒症大鼠肺脏MPO活性,降低脓毒症大鼠血浆内毒素含量；安宫牛黄丸能够显著下调JAK/STAT通路中STAT1和STAT3的mRNA表达,能够显著减弱STATs RNA的结合活性,显著降低JAK/STAT通路的活化程度,同时还能显著下调TNF-α和HMG-1mRNA的表达。
结论：采用CLP法能够成功复制脓毒症大鼠模型；大鼠脓毒症的发病机制可能与JAK/STAT通路高度活化以及由此通路激活的早期TNF-α、晚期炎症介质HMGB-1等炎症介质释放有关,并由此而导致了炎症反应失控,最终可能引起脏器的损害,引发MODS、脓毒症休克等。安宫牛黄丸能够降低脓毒症大鼠模型的死亡率,提高脓毒症休克时大鼠的体温,提高脓毒症大鼠的白细胞计数,对脓毒症大鼠整体有较好的保护作用。同时,安宫牛黄丸能够具有降低脓毒症大鼠血清ALT、AST水平的趋势,能够显著降低脓毒症大鼠血清TB水平,降低脓毒症大鼠肺脏MPO活性、血浆内毒素含量,对脓毒症大鼠主要脏器功能有明显的改善作用,这可能是安宫牛黄丸治疗脓毒症的机制之一。
安宫牛黄丸能够显著下调脓毒症大鼠肝脏、肺脏、肾脏等主要脏器中早期炎症介质TNF-α和晚期炎症介质HMGB-1 mRNA表达；能够显著下调脓毒症大鼠肝脏、肺脏、肾脏等主要脏器中STAT1、STAT3 mRNA表达；还能显著降低JAK/STAT通路中STAT1和STAT3 DNA结合活性,降低JAK/STAT通路的活化程度。这从分子水平进一步阐明了安宫牛黄丸治疗脓毒症的作用机制,为安宫牛黄丸在危重病急救领域中的应用提供了理论基础。
Objective:based on successful replication of sepsis animals, the paper studies on the pathogenesis of sepsis from the level of molecular cell. Using the intervene treat of Angong Niu Huang Wan, the paper will observes how the pill protects the septic rats. On the basis of that, it also will check the pills'mRNA expression of early sepsis inflammatory media TNF-aand later media HMGB-1, also its effect of Janus kinase/signal transducer and activators of transcription (JAK/STAT). The pape r will offer the theoretical foundation for the application of Angong Niu Huang Wa n in injury severity from exploring the mechanism of how Angong Niu Huang Wan treating the sepsis on the basis of molecular mechanism, and deep level target.
Methods:adopting CLP to replicate the sepsis animal model; 90 SPF rats, hal f male and half female, divided into five groups, (1) the control (n=10), get the blo od after anesthesia then euthanize them for the test; (2) the model (n=20), get the blood 24h later after treating the rats with distilled water (10ml/kg) 0.5h before CL P and 6h after CLP, then euthanize them for the test; (3) Angong Niu Huang Wan low, middle and high, each 20 rats, get the blood 24 hours after gastric perfusion (1.0g/kg,2.0g/kg,3.0g/kg),0.5h before CLP and 6h after CLP, then euthanize them for the test; observe each groups and check the death rate and normal behaviors d uring the 24h; the degree of animal autopsy intraperitoneal infection; the rats rectal temperatures 6h,12h and 24h after operation; the WBC of the rats 24h after operati on measured by blood analyzer; the ALT, AST, BUN, Crea, TB levels of the Seru m measured by automatic biochemistry analyzer; the MPO content in the lung meas ured by enzymatic determination; the toxin content in the plasma by limulus polyph emus; the expression of STAT1, STAT3, TNF-αand HMGB-1 of liver, lung and kidney measured by semi-quantitative RT-PCR; the DNA binding activity of STAT1 and STAT2 measured by EMSA.
Results:based on replication of sepsis animal models by CLP, the ill conditio ns of the rats gradually increased and some rats would even die; the activities of ra ts were induced and they no longer gather together to keep warm; they has the feat ures of sleepiness with pio-erection and do not drink water; some rats even suffer t he shortness of breath, pyuria, diarrhea and eye exudate. The cumulative rate of dea th reaches 55% in 24h. Post mortem examination reveals the serious degree of intra peritoneal infection; the models'body temperatures keep in a low condition (core te mperature less then 36℃), get leukopenia (WBC maybe less than 4×109/L) and the ir main organs are seriously damaged (ALT, AST and TB levels of serum and lung MPO activity are obviously higher than the control group); the toxin level in the s epsis rats'serum is very higher than the control group; the DNA activity of STAT1 and STAT 3 of the sepsis rats'main organs also rises obviously, JAK/STAT is al so highly activated in the pathway and meanwhile, the expression of early inflamma tory media TNF-αand later media HMGB-1 is also highly raised.
Angong Niu Huang Wan can improve the normal behaviros of the sepsis rat s, obviouly reduce their death rate, raise their tempeatures during their shock and in crease their WBC count. The pills can lower the ALT and AST levels in the sepsis rats'serum, higly decreased their TB level in the serum, their lungs'MPO activity and the toxin content in their plasma. The pills can reduce JAK obviously. STAT1 and STAT3's mRNA expression in the STAT activation pathway can reduce STAT s'RNA bending activity, the pathway's activation degree of JAK/STAT and meanw hile the Mrna expression of TNF-αand HMGB-1.
Conclusion:the CLP method can successfully replicate the sepsis rate models; the pathogenesis of the septic rats might be related to the higher pathway activatio n of JAK/STAT and the release of early inflammatory media TNF-αand later med ia HMGB-1 caused by the activatio pathway so as to cause the inflammatory effect s out of control and finally lead to the organs damage, MODS and septic shock. A ngong Niu Huang Wan can well protect the sepsis. The possible molecular mechani sms treatment of the pills for sepsis is to reduce the STAT1 and STAT3 expression in the JAK/STAT activation pathway so as to reduce the JAK and STAT's activati on pathway degree, thus reduce the express of related cytokine such as TNF-α, H MGB-1, from JAK/STAT activation pathway, regulate the inflammatory infection tha t is out of control and reduce the inflection damage to organs so as to protect orga nism.
引文
[1] Bone RC,Sprung CL,Sibbald WJ.Definitions for sepsis and organ failure.Crit Car e Med.1992,20,724-726
[2] Levy MM,Fink MP,Marshall JC,et al.2001 SCCM/ESICM/ACCP/ATS/SIS interna tional Sepsis Ddfmitions Conference Crit Care Med,2003;31;1250-1256
林洪远，脓毒症——挑战与对策，中国危重病急救医学，2004；16(6)；325-356
[3]Heithan TH,Bruce CK,Dabid WM,et al.Post-injury multiple organ failure;the role of the gut,Shock,2001;15;l
[4] Karima R,Matsumoto S,Higashi H,et al.The molecular pathogenesis of endotoxic shock and organ failure.Molecular Med Today,1993;3;123
[5] Jarrar D,Chaudry IH,Wang P.Organ Dysfunction following hemorrhage and sepsi s;Mechanisms and therapeutic approaches.Intl J MOL Med, 1999;4;575
[6] Kox W.Immunomodulatory therapies in sepsis.Intensive Care Med,2000;20;s124
[7] Huber TS,Gaines GC,Welborn B,et al.Anticytokine therapies for acute inflammati on and the systemic inflammatory response syndrome:IL-10 and ischemia/reperfusion injury as a new paradigm.Shock.2000;13;434-452
[8] Dell Albani P,Santongelo R,Torrsi L,et al.JAK/STAT signaling pathway mediates cytokine-induced iNOS expression in primary as troglial cell culture.J Neurosci Res, 2001;65;417-424
[9]姚咏明，盛志勇，脓毒症信号转导机制的现代认识，中国危重病急救医学，2003：15(1)：3—6
[10] BenkhartEM,SiediarM.WedeLA,etal,Roleof STAT3 inlipopolysac-charideinduced I L-10 genne expression (J)Jimmunol,2000,165(3):1612-1617
[11]王文江，姚咏明，中医药抗内毒素血症治疗德研究进展，中国中西医结合急救杂志，2004；11(5)：317—319
[12]陈镜台，周海平，中西医结合急症诊治，人民卫生出版社，2003年8月出版。
[13]刘启泰，两种安宫牛黄丸药理作用的研究，中成药研究；1982；(5)：23．
[14]．康毅，等．安宫牛黄丸(针)的药理作用．天津医学院学报，1984；8(3)：6。
[15]王本详，等．安宫牛黄丸的药理作用研究，天津医学院学报，1978；(5)：22。
[16]刘淘，江苏中医，1987；6：33
[17]王松柏．Janus激酶／信号转导和转录激活因子途径与脓毒症的研究进展，中国危重急救医学，2003；15(11)：690
[18]姚咏明，盛志勇，脓毒症信号转导机制的现代认识，中国危重病急救医学，2003，15(1)：3
[19] Imada K,Leonard W J.The JAK/STAT pathway(J).Mol Immunol,2000;37(1);1
[20] Miscia S,Marchisio M,Grili A,et al.Tumor necrosis factor alpha(TNF-activates J AK1/STAT3-STAT5 B signaling through TNFR-1 in human B cells(J).Cell Growth Differ,2002;13(1);13
[21] Riley J K,Takeda K,Akira S,et al;Interleukin-10 receptor signaling through the JAK/STAT pathway(J)J Biol Chem; 1999,274(23); 16513
[22] Andrejko K M,Chen J,Deutschman C S.Intrahepatic STAT-3 activation and acute phase gene expression predict outcome after CLP sepsis in the rat (J).Am J Physi ol,1998;275;G1423
[23] Jacobs AT.Ignarro L J.Lipopolysac-charide-induced expression of interferon-beta mediates the timing of inducible nitric-oxide synthase induction in RAW264.7 macrophages(J) J Biol Chem,2001;76(51);47950.
[24]Marrero M B,Venema V J,He H,et al,Inhibition by the JAK/STAT pathway of IFN gamma-and LPS-stimulated nitric oxide synthase induction in vascular smooth muscle cells(J) Biochem Biophys Res Commun,1998;252(2);508
[25]姚胜，姚咏明，李红云，等．烫伤脓毒症大鼠肝、肺组织STAT活化规律及意义(J)解放军医学杂志，2002；27(9)：763 ． ：
[26] Benkhart E M,Siedlar M,WedelA,et al.Role of STAT3 in lipopolysac-charide-induced IL-10 gene expression (J) J Immunol,2000;165(3);1612
[27]王松柏，姚咏明，陈劲松．严重腹腔感染大鼠JAK／STAT通路活化与多器官功能损害的关系，解放军医学杂志2004；29(1)：42—44
[28] Matsukawa A,Kaplan MH,Hogaboam CM,et al.Pivotal role of signal transducera ndactivator of transcription STAT4 and STAT6 in the innate immune response during sepsis (J).J Exp Med,2001;193(6);679-688
[29] Riley JK,Takeda K,Akira S, et al.Interleukin 10 receptor signaling through the JAK/STAT pathway (J).J Biol Chem, 1999;274(23); 16513-16521
[30] Reddy J,Chastagner p,Fiette L,et al.IL-2 induced tumornecrosis factor beta expression,Further analysis in the IL-2 knockout model,and comparison with TNF alpha,lymphotoxin beta.TNFRl and TNFR2 modulation(J).Intmmunology,2001;13(2);137-147
[31] Wang H, Bloom O,Zhang M,et al.HMGBB1 as a late mediator of endotoxin lethality in mice(J),Science,1999,285;248-251
[32] Fang Wen Hui,Yao Yongming,Shi Zhiguo,et al.The significance ofchanges in high mobility groupl proteinm RNA expression in rat safterthermal injury(J).Shock,2002;17;329-333
[33]李红云，姚咏明，施志国，等．高迁移率族1蛋白在烫伤后金黄色葡萄球菌脓毒症中的改变与意义．中华实验外科杂志,2001；15(3)；147—149
[34]张立天，姚咏明，陆家齐，等．脓毒症大鼠HMGB1基因表达及其与内毒素血症的关系(J)．中华普通外科杂志,2002；17；556-558
[35]王松柏，姚咏明，董宁．JAK／STAT通路介导脓毒症大鼠肝组织高迁移率族蛋白B1 mRNA表达的研究，中国危重并急救医学,2003；15(3)；147-149
[36]刘小波，马布仁。应用产色基质偶氮法筛选内毒素中草药(J)，实用中西医结合杂志，1995；8(8)；583
[37]谢恬．大黄对家兔内毒素发热及血浆cAMP和cGMP含量的影响(J)，上海中医药杂志，1991；5(2)；46
[38]陈德昌，李红江，乔林，等．大黄对创伤后脓毒症大鼠肝细胞线粒体功能的影响(J)，中国中西医结合急救杂志,2002；9(1)；911
[39]余林中，吴锐，黄泳，等。凉膈散对家兔内毒素温病模型的解毒作用研究(J)。中药药理与临床,1996；(5)；46
[40]耿耘，马超英，肖诚，等。牛珀至宝丹对内毒素休克大鼠血液流变的影响(J)，中国危重病急救医学，1997；9(12)；715
[41]崔克亮，曹书华，王今达．大承气汤对多器官功能障碍综合征防治作用的临床研究(J)．中国中西医结合急救杂志,2003；10(1)；12
[42]任成山．脓毒症的发病机制(J)。Chin J Care Med：Oct．2005,Vol 25,No．10
[43] Wang JE, Jorgensen PF,Almlof M,et al.Peptidoglcan and lipoteichoic acid from Straphycococcus aureus induce tumor netrosis factor alpha,interleakin 6(IL-6),and IL-10,Production in both T cells and monocytes in a human whole blood model.Infect,Immun,2000,68(7):39-41
[44]舒强，方学明,Stueber,F．手术后严重感染患者肿瘤坏死因子基因微卫星多态性及其与预后关系的研究．中华医学杂志,2000,80：193-195．
[45] Fang X M,Schroder S,Hoete A,et al.Comarison of two polymorphisms of the interleukin-1 gene family:inteleukin-l receptor antogonise polymorphism contributes to susceptibility to seuere sepsis.Crit Care Med,1999,27(7):1330-1334. [46] Stuber F,Petersen M,Bokelmanmm,F,et al.A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentratio ns ant outcome of patients with severe sepsis,Cris Care Med, 1996,24:38-42.
[47] Wright SD,Ramso RA,Tobias PS,et al.CD14,a receptor fou complexes of lipopo lysaccharides(LPS) and LPS binding protein.Science,1990,249(4975):1431
[48] Pugin,J,Heumann ID,Tomasz A,et al.CD14 is a pattern recognition receptor. Immunity,1994,1(6):509-516.
[49] Devitt A,Moffatt OD,Raykundalia C,et al.Human CO14 mediates recognition an d phagocytois of apoptotic cells.Nature,1998,392(6675):505-509.
[50] Yu B,Hailman E,Wright SD.Lipopolysaccharide binding protein and soluble CD14 catalyze exchange of Phospholipids J.Chin,Invest,1997(99)315-324.
[51] 张佃良.脓毒症的分子机制.国外医学，外科分册，2002(1):1-4.
[52] Leturcq DJ,Moriarty AM,Talbott G,et al.Antibodies against CD14 protect primat es from endotoxin-induced shock J Clin.Invest 1996,98:1533-1538.
[53] Kaisho T,Akira S.Pleiotropic function of Toll-like receptor.Microbes and Infecti on.2004,6(15):1388-1394.
[54] Philpott DJ,Girardin SE.The role of Toll-like receptors and Nod proteins in bac terial infection,Molecular.Immunology,2004,41(11): 1099-1108.
[55] Goldstein DR,Toll-like receptor and other links between immute and acquired a lloimmunity Current Opinion in Immunology,2004,16:538-544.
[56] 邓敏，陈晓飞.Toll样受体与常见病原菌感染之间关系的研究进展.2005，17(5):598-600.
[57] Beulter B,Poltorak A.Sepsis and evolution of the innate immune response.Crit Care Med,2001,29(7Suppl):S2-6;discussion S6-7.
[58] American College of Chest Physicians/Society of Critical Care Medicine Conse nsus Conference;definitions for sepsis and organ failure and guidelines for the use o f innovative therapies in sepsis.Crit Care Med,1992,20(6):864-874
[59] 姚咏明，柴家科，盛志勇.烧伤脓毒症的诊断标准与防治.中华烧伤杂志，2003，19(2):65-66
[60] Rivers E,Nguyen B,Havstad S,et al.Early goal-directed therapy in the treatment of severe sepsis and septic shock..N Engl J Med,2001,345:1368-1377
[61] Dellinger RP,Carlet JM,Masur H,et al.Surviving sepsis campaign guidelines for management of severe sepsis and septic shock.Crit Care Med,2004,32:858-873.
[62] Macarthur RD,Miller M, Albertson T,et al..Adequacy of early empiric antibiotictreatment and survival insevere sepsis:experience from the MONARCS trial. Clin In fect Dis,2004,38:284-288.
[63] Trautmann M,Zick R,Rukavina T,et al.Antibiotic-induced release of endotoxin:in vitro comparison of meropenem and other antibiotics.J Antimicrob Chemother,1998, 41(2):163
[64] Mattie H,Stuertz K,Nau R,et al.Pharmacodynarmics of antibiotics with respect to bacterial killing of and release of lipoteichoic acid by Streptococcus pneumoniac.J Antimicrob Chemother,2005,56(1): 154-159.[65 ] Reuben AD,Appelboam AV,Higginson I,et al.Earlay goal-directed therapy:a UK perspective.Emerg Med J,2006,23(11):828-832.
[66]Taylor RW,Manganaro L,O' Brien J,et al.Impact of allogenic packed red blood cell transfusion on nosocomial infection rates in critically ill patient.Crit Care Med,2 002,302249-2254.
[67] Cowin HL,Gettinger A,Pearl R,et al.Efficacy of recombinant human erythropoiet in in critically ill patients.JAMA,2002,288:2827-2835.
[68] Herbert PC,Wells G,Blajchman MA,et al.A multicentre randomized controlled clinical trial of transfusion requirements in critical care.N Engl J Med,1999,340(6):409 -417.
[69] Bernard GR,Wheeler AP,Russell JA.et al.Effects of ibuprofen on the physiology and survival of patients with sepsis.N Engl J Med,1997,336:912.
[70] Balk RA.Severe sepsis and septic shock:definitions ,epidemiology,and clinical manifestations.Crit Care Clin,2000,16:179-192.
[71] Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome.The Acute Respiratory Distress Syndrome Network.N Engl J Med,2000,3442(18):1301-1308
[72] Shenker Y,Skatrud JB.Adrenal insufficiency in critically ill patients.Am J Respir Crit Care Med,2001,163(7): 1520-1523.
[73] Bernard GR,Vincent JL,Laterre PF,et al.Efficacy and safety of recombirtant human activated protein C for severe sepsis.N Engl J Med,2001,344(10):699-709.
[74] Annane D,Sebille V,Charpentier C,et al.Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock.JAMA,2002,288(7):862-871
[75]刘超乾，盛湲。脓毒症治疗的新进展．国际外科学杂志．2007，34(12)：853—856．
[76] Hanrahian AH,Oseni TS,Arafah BM.Measurements of serum free Cortisol in crit ically ill patients.N Engl J Med,2004,350(16): 1629-1638.
[77] Vincent JL,Angus DC,Artigas A,et al.Effects of drotrecogin alfa(activated) on organ dysfunction in the PROWESS trial.Crit Care Med,2003,31(3)834-840.
[78] Abraham E ,Laterre PF,Gaeg G,et al.Drotrecogin alfa(activated) for adults with severe sepsis and a low risk of death.N Engl J Med,2005,353(3):1332-1341
[79] Ely EW,Laterre PF,Angus DC,et al.Drotrecogin alfa (activated) administration scross clinically important subgroups of patients with severe sepsis.Crit Care Med,2003,31(3):968-969.
[80] De Jonge E,Schultz MJ,Spanjaard L,et al.Effects of selective decontamination of digestive tract on mortality and acquisition ofresistant bacteria in intensive care:a randomized controlled trial.Lancet,2003,362(9389)1011-1016.
[81] Gao F,Gao E,Yue TL,et al.Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemia-reperfusion:the roles of P13-kinase,Akt,and endothelial nitric oxide synthase phosphorylation .Circulation,2002,105(12):1497-1502.
[82] Van den Berghe G,Wouters P,Weekers F,et al.Intensive insulin therapy in critically ill patients .N Engl J Med,2001,345(19):1361-1367.
[83] Van den Berghe G,Wouters P,Bouillon R,et al.Outcome benefit of intensive insulin therapy in the critically ill: Insulin dose versus lycaemic control. Crit Care Med,2003,31(2):359-366.
[84]兰海涛，刘清泉．脓毒症的中医理论探讨．中华中医药学会急诊分会第二届换届选举暨学术研讨会论文集，151—154.
[85]刘清泉，蓝海涛．中医对脓毒症的认识及辨证体系的研究．中华中西医临床杂志．2004,4(3)261-264．
[86]郭仁．《伤寒论》六经病变本质探讨．山东中医杂志,2005,9,24(9)：521-523．
[87]李彩月，李成福，等．中医外感热病对感染性全身炎症反应综合症的认识．中国中西结合急救杂志．2002,9(2)：63-64．
[88]王今达，李志军，李银平。从“三证三法“辨证论治脓毒症．中国危重病急救医学．2006,18(11)：643—645．
[89]刘清泉．对脓毒症中医病机特点及治法的认识．北京中医,2007,26(4)：198-200．
[90]姜树民，王哲．中医药通报,2007,6(4)：30-32．
[91]夏燕亮，刘昕．丹参对大鼠脓毒症急性肺损伤发生中TNF-Ad影响及对肺的保护作用。中药药理与临床,2004：20(6)15—17．
[92]黄琰．脓毒症发病状况及症候特点的临床研究．北京中医药大学硕士论文．
[93]魏利召，郑江，蒋栋能．赤芍拮抗内毒素活性的实验研究．中国临床药理学与治疗学，2005,10(3)：326-328．
[94]张艺平，韩鹏冲药抗内毒素研究进展．中国中西医结合急救杂志,2001，8(2)：122—124．
[95]戴锡珍，高淑娟．黄连解毒汤体外抗内毒素作用的实验研究．中国中医基础理论医学杂志,2000,6(5)：31-32．
[96]曹书华，高红梅,王永强．“神农33号”对多器官功能障碍综合征大鼠细胞因子的影响．中哈急诊医学杂志,2003,12(2)：94-96．
[97]郭昌星，杨兴易，林兆奋，等．血府逐瘀汤对全身炎症反应综合征患者血氧自由基的影响．中国中西医结合急救杂志,2002,9(12)：720-722．
[98]王文俊，吴咸中．化解冲剂对脓毒症大鼠神经肽及细胞因子的调节作用．中国免疫学杂志，1997,1 3(2)：84-86．
[99]陈海龙，吴咸中，关风林，等．中医通里攻下法对多器官功能不全综合征时肠道屏障功能保护作用的实验研究．中国中西医结合杂志,2000,20(2)：12．
[100]姚睿智，谢晓华，陈铭．通腑泻热灌肠剂对急腹症脓毒症术后血清C反应蛋白的影响-广州中医药大学学报,2002,19(2)：96-98． ．
[101]万幸，刘倩娴,王培训．大承气汤对全身炎症反应干预作用的实验研究．广州中医药大学学报,2003,20(2)：153-156．
[102]于泳浩，崔乃强，傅强，等．大承气汤颗粒对重型脓毒症促炎-抗炎反应平衡的影响。中国中西医结合外科杂志,2004,10(6)：409-412．
[103]曹书华，王今达．大承气汤在多器官功能障碍综合征治疗过程中的免疫调节作用。中华创伤杂志,2004,20(12)720-723
[104]李军茹．大柴胡汤加味治疗多器官功能失常综合征及对血浆内毒素影响的观察。浙江中医杂志,2005,6：264-265．
[105]李蓉，程建详。参麦注射液对盲肠结扎并穿孔致脓毒症大鼠的免疫调节作用。现代中西医结合杂志,2004,13(16)：2135-2136．
[106]靳桂贞，潘雪。解热硝烟胶囊的药理作用初探．中药通报，1987,12(1)：2
[107]叶祖光,王金华，王跃生，等．安宫牛黄丸及其简化方的药效学研究．中国中药杂志．2003,28(7)：636．
[108]蒋玉凤，黄启福，严京，等．清开灵对加图内毒素性发热和脑脊液cAMP含量的影响．北京中医药大学学报，1994,17(5)：66．
[109]韦文哲，吴树勋，张建树，等．牛黄醒脑注射液药理作用的初步研究．中成药研究，1981，(6)：32．
[110]朱培纯，等．清开灵注射液对大白鼠脑内蓝斑乙酰胆碱酯酶及单胺氧化酶的影响。中成药研究．1981；(3)：33．
[111]朱承喜，侯家玉，金恩波，等．安宫牛黄丸及清开灵注射液对实验性氨昏迷动物皮层电图的影响．中西医结合杂志，1989,9(12)：739．
[112]．刘涛，沈凤阁，王灿，等．安宫牛黄丸对兔脑脊液乳酸脱氢酶、脑组织化学乳酸脱氢酶的影响．江苏中医，1987,(6)：33
[113]黄玉芳，邓郗年，何原惠，等．安宫牛黄丸对脑水肿家兔脑内酶的影响．南京中医学院学报，1991，7(2)：92．
[114]白丽敏，孙红梅，朱培纯．等．清开灵注射液对实验性脑出血大鼠闹内P物质的影响，北京中医药大学学报，1996,19(6)：67．
[115]何原惠，黄玉芳，郑郗年，等．安宫牛黄丸对实验性脑水肿动物肝脏的影响．江苏中医，1992,(12)：38．
[116]叶百宽，贲长恩，俞慧珠，等．清开灵对实验性肝损伤修复作用的组织学和组织化学的探讨，中华内科杂志，1981,20(1)：38．
[117]傅志慧．安宫牛黄丸治疗脑卒中急性期神昏的临床观察．新中医，1993,25(12)：33．
[118]于风云，李秀梅，孙莹．等．安宫牛黄丸灌肠治疗中风病人53例临床报告。中医药信息，1993,(2)：33．
[119]邢峰丽，李青，张伟，等．安宫牛黄丸治疗脑中风34例临床观察．河北中医,2005,27(1)：13-14．
[120]李向荣，李小文．安宫牛黄丸治疗蛛网膜下腔出血后脑血管痉挛疗效观察．中国中西医结合急救杂志，19966(10)：479-480．
[121]高大硕，刘本春．安宫牛黄丸治疗颅脑损伤术后高热昏迷20例．中西医结合实用临床急救，1997,4(11)：498．
[122]傅朗林。安宫牛黄丸治疗肺性脑病15例．中西医结合实用临床急救．1996,3(12)556．
[123]熊曼琪，彭万年。安宫牛黄丸治验五则．中国医药学报．1988,(4)：44．
[124]虞坚尔，邱根详，李晓葵．等．安宫牛黄丸在儿科临床的再运用．上海中医药杂志，1994,5：18—19。
[125]张文辉，清开灵注射液治疗上呼吸道感染临床疗效观察．河南医药信息,2001，9(18)39-40.
[126]陈峰霖。安宫牛黄丸治疗顽固性癌性高热的疗效观察．实用中西医结合杂志．1994，7(9)：545．
[127]黄金平。安宫牛黄丸治疗农药中毒．浙江中医杂志，1985,20(8)：376．
[128]王肖蓉，孙荣智．安宫牛黄丸治疗败血症的体会．河南医药信息,2002,10(11)：6．
[129]匡耀祖．以安宫牛黄丸为主治疗黄疸型肝炎．江西中医药，1988,(6)：17．
[130]闫吉文．清开灵配伍胃苓汤治疗急性黄疸型肝炎疗效观察．黑龙江中医药，1991，(3)：34
[131]于新芳,王丽娟．病毒唑和安宫牛黄丸治疗流行性乙型脑炎疗效观察．中西医结合实用临床急救．1996,3(10)：452．
[132]贾印宝．安宫牛黄丸治疗流行性出血热．中成药，1993,(6)：44．
[133]王春英，丁汉和，李作平．安宫牛黄丸治疗流行性出血热的初步观察．临沂医专学报．1993,15：100．
[134]李爽．清开灵的药理作用与临床应用。现代中西医结合杂志,2009,18(1)：108-110．
[135]王永恒．安宫牛黄丸在颅脑损伤中对意识障碍恢复的疗效观察．中西医结合杂志．1989，9(12)：726．
[136]周杰，徐蔚，董涛，等．中西医结合治疗重型颅脑损伤68例．中国煤炭工业医学杂志．2006,9(10)：1099．
[137]潘华新，王培训，王宁生．安宫牛黄丸及其类方临床应用概况．新中医,2001,33(12)：64-66．
[138]史宇辉．肿瘤坏死因子研究进展。河北医科大学学报，1998,19(4)：249-252．
[139]Spriggs DR,Zaheer T,Zhong W,et al.Tumor necrosis factor and interleukin-6 mRNA expression in neonatal Lewvis rat Schwann cells.Marcel Dekker Ink, 1991,72(1):33-34.
[140] Hamish R.Michie MB,Kirk RM,et al.Detection of circulation tumor necrosis factor after endotoxin administration.New Eng J Med, 1988,318(2): 1841.
[141] Wang H,Bloom O,Zhang M,et al.HMG-1 as a late mediator of endotoxin lethality in mice.Science,1999,285(5425):248-251.
[142]梁晋川．高迁移率族蛋白1的研究进展。医学综述,2006,12(11)：653—656．
[143]Wang H,Yang H,Tracey KJ.Extracellular role of HMGB1 in inflammation and sepsis.J Intern Med,2004,255(3):320-331.
[1]陈德昌,李红江,乔林,等.大黄对创伤后脓毒症大鼠肝细胞线粒体功能的影响(J),中国中西医结合急救杂志,2002；9(1)；911.
[2]沈恬.大黄对家兔内毒素发热及血浆cAMP和cGMP含量的影响(J),上海中医药杂志,1991；5(2)；46.
[3]余林中,吴锐,黄泳,等.凉膈散对家兔内毒素温病模型的解毒作用研究(J).中药药理与临床,1996；(5)；46
[4]耿耘,马超英,肖诚,等.牛珀至宝丹对内毒素休克大鼠血液流变的影响(J),中国危重病急救医学,1997；9(12)；715
[5]Wichman KA,Bauce AE,Chaudry IH,et al.Sepsis and septic shock:A review of 1 aboratory models and a proposal.J Surg Res,1980,29:189
[6]金惠铭.盲肠结扎穿刺后的大鼠败血症模型.中国病理生理学杂志.1990,6(2)：126-127.
[7]Simon R,Wetzel N,Winsey K,et al.Supplemental dietary tyrosine in sepsis and ac ute hemorrhagic shock.Arch Surg,1987,122:78.
[8]王肖蓉,孙荣智.安宫牛黄丸治疗败血症的体会.河南医药信息,2002,10(11)：6.
[9]Bone RC Sprung CL,Sibbald WJ.Definitions for sepsis and organ failure.Crit Ca re Med,1992,20,724-726.
[10]Levy MM,Fink MP,Marshall JC,et al.2001 SCCM/ESICM/ACCP/ATS/SIS intern ational Sepsis Ddfinitions Conference Crit Care Med,2003;31;1250-1256.
[11]American College of Chest Physicians/Society of Critical Care Medicine Conse nsus Conference;definitions for sepsis and organ failure and guidelines for the use o f innovative therapies in sepsis.Crit Care Med,1992,20(6):864-874.
[12]Tracey KJ,Cerami A.Tumor necrosis factor,other cytokine and disease.Annu Rev Cell Biol1993,9:317-343.
[13]Tracey KJ,Beutler B,Lowry SF,et al.Shock and tissue injury induced by recomb inant human cachectin. Science,1986,234:470-474.
[14]Bone RC.The pathogenesis of sepsis.Ann Intern Med,1991,115:457-469.
[15]Nathan CF.Sectrtory products of macrophages.J Clin Invest,1987,79:318-326.
[16]Wang H,Tracey KJ.Tumor necrosis factor,interleukin-6,macrophage migration inh ibitory factor,and macrophage inflammatory protein-1 in inflammation,In Gallin JI,Sn yderman R(ed)Inflammation:Basic Principle and Clinical Correlates.3rd Edition Philade lphia:Lippincott,Williams and Wilkins,1999:417-485.
[17]陈奇.中药药理研究方法学.,第2版.北京：人民卫生出版,2006,832.
[18]王同明,李玉玲,等.胆色素代谢与黄疸.生物化学与检验技术.江苏科学技术出版社,1995.
[19]王明海,张义胜,赵国海.等.实验性大鼠重症急性胰腺炎早期肺组织中MDA／MPO的变化〖J〗.皖南医学院学报,2006,25(2)：81-83.
[20]王世锋,王文波,朱嘉.高压氧暴露对小鼠肺组织匀浆髓过氧化物酶活性的影响〖J〗.海军医学杂志,2005,26(2)：102-103.
[21]HIROYUKI Y,ALEX B,WILLIAM G,et al.Enhanced pulmonary expression of CXC chemokines during hepatic ischemia/reperfusion-induced lung injury in mice.J S ur Res,1999,81(1):33-37.
[22]张佃良,黎介寿,江志伟.脓毒症的分子机制.国外医学外科学分册,2002,29(1)1-3.
[23]杨英详.脂多糖结合蛋白在脓毒症中的作用及临床意义〖J〗.国外医学外科学分册,1999,26(3)：131-134.
[24]Heithan TH,Bruce CK,Dabid WM,et al.Post-injury multiple organ failure;the rol e of the gut,Shock,2001,15:1.
[25]Karima R,Matsumoto S,Higashi H,et al.The molecular pathogenesis of endotoxi c shock and organ failure.Molecular Med Today,1993,3:123.
[26]任成山.脓毒症的发病机制(J)。Chin J Care Med.Oct.2005,Vol 25,No.10
[27]F.M.奥斯伯,R.布伦特,R.E.金斯顿,等.精编分子生物学实验指南,第五版.北京：科学出版社,2008.
[28]杨丽萍,姚咏明,盛志勇.脓毒症发病的炎症反应与免疫紊乱机制.感染、炎症、修复,2008,9(1)：48-51.
[29]Hamish R.Michie MB,Kirk RM,et al.Detection of circulation tumor necrosis fac tor after endotoxin administration.New Eng J Med,1988,318(2):1841.
[30]Matsukawa A,Kaplan MH,Hogaboam CM,et al.Pivotal role of signal transducera ndactivator of transcription STAT4 and STAT6 in the innate immune response durin g sepsis (J).J Exp Med,2001;193(6);679-688.
[31]Riley JK,Takeda K,Akira S, et al.Interleukin 10 receptor signaling through the JAK/STAT pathway (J).J Biol Chem,1999;274(23); 16513-16521
[32]Reddy J,Chastagner p,Fiette L,et al.IL-2 induced tumornecrosis factor beta expr ession,Further analysis in the IL-2 knockout model,and comparison with TNF alpha,l ymphotoxin beta.TNFR1 and TNFR2 modulation(J).Intmmunology,2001;13(2);137-147
[33]Wang H,Bloom O,Zhang M,et al.HMG-1 as a late mediator of endotoxin lethal ity in mice.SCIENCE,1999,285:248-251
[34]Wang H,Yang H,Tracey KJ.Extracellular role of HMGB1 in inflammation and sepsis,Intern Med,2004,255:320:331.
[35]Andersson U,Wang H,Palmblad K,et al.High mobility group 1 protein stimulate s proinflammatory cytokine synthesis in human monocytes.J Exp Med,2000,192(4): 565-570.
[36]Yang H,Ochani M,Li J,et al.Reversing established sepsis with antagonists of en dogenous high mobility group box 1.Proc Natl Acad Sci USA.2004,101:296-301.
[37]Venkataraman R,Kellum JA,Song M,et al.Resuscitation with Ringer's ethylpyruv ate solution prolongs survival and modulates plasma cytokine and nitrite/nitrate conc entrations in a rat model of lipopllysaccharide induced shock.Shock,2002,18:507-512
[38]方文慧,姚咏明,施志国,等.严重烫伤后高迁移率族蛋白-1基因表达的改变及意义.中华外科杂志,2001,39：137-140.
[39]李红云,姚咏明,施志国,等.高迁移率族-1蛋白在烫伤后金黄色葡萄球菌脓毒症中的的改变与意义.中华实验外科杂志,2001,18：336-338.
[40]Quimby F,Nguyen HT.et al.Aninmal studies of toxic shock syndrome CRC Crit Rev Microbiol,1985,12:1-44.
[41]Shiranee S,Cohen J.Gram-positive sepsis:Mechanisms and differences from gram-negative sepsis.Infect Dis Clin Nor Am,1999,13:397-412.
[42]王松柏.Janus激酶／信号转导和转录激活因子途径与脓毒症的研究进展,中国危重急救医学,2003,15(11)：690
[43]姚咏明,盛志勇,脓毒症信号转导机制的现代认识,中国危重病急救医学,2003,15(1)：3
[44]Mada K,Leonard W J.The JAK/STAT pathway(J)Mol Immunol,2000;37(1);1
[45]Miscia S,Marchisio M,Grili A,et al.Tumor necrosis factor alpha (TNF-activates) JAK1/STAT3-STAT5 B signaling through TNF R-1 in human B cells.Cell Growth Differ,200213(1):13.
[46]Riley J K,Takeda K,Akira S,et al;Interleukin-10 receptor signaling through the JAK/STAT pathway(J).J Biol Chem; 1999,274(23);16513.
[47]Andrejko K M,Chen J,Deutschman C S.Intrahepatic STAT-3 activation and acut e phase gene expression predict outcome after CLP sepsis in the rat (J).Am J Physi ol,1998;275;G1423
[48]Jacobs AT.Ignarro L J.Lipopolysac-charide-induced expression of interferon-beta mediates the timing of inducible nitric-oxide synthase induction in RAW264.7 macro phages(J) J Biol Chem,2001;76(51);47950.
[49]Arrero M B,Venema V J,He H,et al,Inhibition by the JAK/STAT pathway of I FN gamma-and LPS-stimulated nitric oxide synthase induction in vascular smooth m uscle cells(J) Biochem Biophys Res Commun,1998;252(2);508.
[50]姚胜,姚咏明,李红云,等.烫伤脓毒症大鼠肝／肺组织STAT活化规律及意义(J)解放军医学杂志,2002；27(9)：763.
[51]Benkhart E M,Siedlar M,Wedel A,et al.Role of STAT3 in lipopolysac-charide-induced IL-10 gene expression (J) J Immunol,2000;165(3);1612
[52]Matsukawa A,Kaplan MH,Hogaboam CM,et al.Pivotal role of signal transducer and activator of transcription STAT4 and STAT6 in the innate immune response dur ing sepsis (J).J Exp Med,2001;193(6);679-688
[53]Streetz K L;Wustefeld;Klein C;et al.Mediators of inflammation and acute phase response in the liver.Cell-Mol-Biol,2001;47(4):661-673.
[54]王松柏,姚咏明,董宁,等.JAK／STAT通路介导脓毒症大鼠肝组织高迁移率族蛋白B1 mRNA表达的研究.中国危重病急救医学,2003,15：147-149.
[55]林洪远,脓毒症——挑战与对策,中国危重病急救医学,2004；16(6)；325-356
[56]Heithan TH,Bruce CK,Dabid WM,et al.Post-injury multiple organ failure;the rol e of the gut,Shock,2001;15;1
[57]Parima R,Matsumoto S,Higashi H,et al.The molecular pathogenesis of endotoxic shock and organ failure.Molecular Med Today,1993;3;123
[58]Jarrar D,Chaudry IH,Wang P.Organ Dysfunction following hemorrhage and seps is;Mechanisms and therapeutic approaches.Intl J MOL Med,1999;4;575.
[59]Huber TS,Gaines GC,Welborn B,et al.Anticytokine therapies for acute inflamma tion and the systemic inflammatory response syndrome:IL-10 and ischemia/reperfusio n injury as a new paradigm.Shock.2000;13;434-452.
[60]Dell Albani P,Santongelo R,Torrsi L,et al.JAK/STAT signaling pathway mediat es cytokine-induced iNOS expression in primary as troglial cell culture.J Neurosci R es,2001;65;417-424.
[61]姚咏明,盛志勇,脓毒症信号转导机制的现代认识,中国危重病急救医学,2003：15(1)：3-6.
[62]BenkhartEM,SiediarM.WedeLA,etal,Roleof STAT3 inlipopolysac-charideinduced I L-10 genne expression (J)Jimmunol,2000,165(3):1612-1617.
[2] Levy MM,Fink MP,Marshall JC,et al.2001 SCCM/ESICM/ACCP/ATS/SIS interna tional Sepsis Ddfmitions Conference Crit Care Med,2003;31;1250-1256
林洪远，脓毒症——挑战与对策，中国危重病急救医学，2004；16(6)；325-356
[3]Heithan TH,Bruce CK,Dabid WM,et al.Post-injury multiple organ failure;the role of the gut,Shock,2001;15;l
[4] Karima R,Matsumoto S,Higashi H,et al.The molecular pathogenesis of endotoxic shock and organ failure.Molecular Med Today,1993;3;123
[5] Jarrar D,Chaudry IH,Wang P.Organ Dysfunction following hemorrhage and sepsi s;Mechanisms and therapeutic approaches.Intl J MOL Med, 1999;4;575
[6] Kox W.Immunomodulatory therapies in sepsis.Intensive Care Med,2000;20;s124
[7] Huber TS,Gaines GC,Welborn B,et al.Anticytokine therapies for acute inflammati on and the systemic inflammatory response syndrome:IL-10 and ischemia/reperfusion injury as a new paradigm.Shock.2000;13;434-452
[8] Dell Albani P,Santongelo R,Torrsi L,et al.JAK/STAT signaling pathway mediates cytokine-induced iNOS expression in primary as troglial cell culture.J Neurosci Res, 2001;65;417-424
[9]姚咏明，盛志勇，脓毒症信号转导机制的现代认识，中国危重病急救医学，2003：15(1)：3—6
[10] BenkhartEM,SiediarM.WedeLA,etal,Roleof STAT3 inlipopolysac-charideinduced I L-10 genne expression (J)Jimmunol,2000,165(3):1612-1617
[11]王文江，姚咏明，中医药抗内毒素血症治疗德研究进展，中国中西医结合急救杂志，2004；11(5)：317—319
[12]陈镜台，周海平，中西医结合急症诊治，人民卫生出版社，2003年8月出版。
[13]刘启泰，两种安宫牛黄丸药理作用的研究，中成药研究；1982；(5)：23．
[14]．康毅，等．安宫牛黄丸(针)的药理作用．天津医学院学报，1984；8(3)：6。
[15]王本详，等．安宫牛黄丸的药理作用研究，天津医学院学报，1978；(5)：22。
[16]刘淘，江苏中医，1987；6：33
[17]王松柏．Janus激酶／信号转导和转录激活因子途径与脓毒症的研究进展，中国危重急救医学，2003；15(11)：690
[18]姚咏明，盛志勇，脓毒症信号转导机制的现代认识，中国危重病急救医学，2003，15(1)：3
[19] Imada K,Leonard W J.The JAK/STAT pathway(J).Mol Immunol,2000;37(1);1
[20] Miscia S,Marchisio M,Grili A,et al.Tumor necrosis factor alpha(TNF-activates J AK1/STAT3-STAT5 B signaling through TNFR-1 in human B cells(J).Cell Growth Differ,2002;13(1);13
[21] Riley J K,Takeda K,Akira S,et al;Interleukin-10 receptor signaling through the JAK/STAT pathway(J)J Biol Chem; 1999,274(23); 16513
[22] Andrejko K M,Chen J,Deutschman C S.Intrahepatic STAT-3 activation and acute phase gene expression predict outcome after CLP sepsis in the rat (J).Am J Physi ol,1998;275;G1423
[23] Jacobs AT.Ignarro L J.Lipopolysac-charide-induced expression of interferon-beta mediates the timing of inducible nitric-oxide synthase induction in RAW264.7 macrophages(J) J Biol Chem,2001;76(51);47950.
[24]Marrero M B,Venema V J,He H,et al,Inhibition by the JAK/STAT pathway of IFN gamma-and LPS-stimulated nitric oxide synthase induction in vascular smooth muscle cells(J) Biochem Biophys Res Commun,1998;252(2);508
[25]姚胜，姚咏明，李红云，等．烫伤脓毒症大鼠肝、肺组织STAT活化规律及意义(J)解放军医学杂志，2002；27(9)：763 ． ：
[26] Benkhart E M,Siedlar M,WedelA,et al.Role of STAT3 in lipopolysac-charide-induced IL-10 gene expression (J) J Immunol,2000;165(3);1612
[27]王松柏，姚咏明，陈劲松．严重腹腔感染大鼠JAK／STAT通路活化与多器官功能损害的关系，解放军医学杂志2004；29(1)：42—44
[28] Matsukawa A,Kaplan MH,Hogaboam CM,et al.Pivotal role of signal transducera ndactivator of transcription STAT4 and STAT6 in the innate immune response during sepsis (J).J Exp Med,2001;193(6);679-688
[29] Riley JK,Takeda K,Akira S, et al.Interleukin 10 receptor signaling through the JAK/STAT pathway (J).J Biol Chem, 1999;274(23); 16513-16521
[30] Reddy J,Chastagner p,Fiette L,et al.IL-2 induced tumornecrosis factor beta expression,Further analysis in the IL-2 knockout model,and comparison with TNF alpha,lymphotoxin beta.TNFRl and TNFR2 modulation(J).Intmmunology,2001;13(2);137-147
[31] Wang H, Bloom O,Zhang M,et al.HMGBB1 as a late mediator of endotoxin lethality in mice(J),Science,1999,285;248-251
[32] Fang Wen Hui,Yao Yongming,Shi Zhiguo,et al.The significance ofchanges in high mobility groupl proteinm RNA expression in rat safterthermal injury(J).Shock,2002;17;329-333
[33]李红云，姚咏明，施志国，等．高迁移率族1蛋白在烫伤后金黄色葡萄球菌脓毒症中的改变与意义．中华实验外科杂志,2001；15(3)；147—149
[34]张立天，姚咏明，陆家齐，等．脓毒症大鼠HMGB1基因表达及其与内毒素血症的关系(J)．中华普通外科杂志,2002；17；556-558
[35]王松柏，姚咏明，董宁．JAK／STAT通路介导脓毒症大鼠肝组织高迁移率族蛋白B1 mRNA表达的研究，中国危重并急救医学,2003；15(3)；147-149
[36]刘小波，马布仁。应用产色基质偶氮法筛选内毒素中草药(J)，实用中西医结合杂志，1995；8(8)；583
[37]谢恬．大黄对家兔内毒素发热及血浆cAMP和cGMP含量的影响(J)，上海中医药杂志，1991；5(2)；46
[38]陈德昌，李红江，乔林，等．大黄对创伤后脓毒症大鼠肝细胞线粒体功能的影响(J)，中国中西医结合急救杂志,2002；9(1)；911
[39]余林中，吴锐，黄泳，等。凉膈散对家兔内毒素温病模型的解毒作用研究(J)。中药药理与临床,1996；(5)；46
[40]耿耘，马超英，肖诚，等。牛珀至宝丹对内毒素休克大鼠血液流变的影响(J)，中国危重病急救医学，1997；9(12)；715
[41]崔克亮，曹书华，王今达．大承气汤对多器官功能障碍综合征防治作用的临床研究(J)．中国中西医结合急救杂志,2003；10(1)；12
[42]任成山．脓毒症的发病机制(J)。Chin J Care Med：Oct．2005,Vol 25,No．10
[43] Wang JE, Jorgensen PF,Almlof M,et al.Peptidoglcan and lipoteichoic acid from Straphycococcus aureus induce tumor netrosis factor alpha,interleakin 6(IL-6),and IL-10,Production in both T cells and monocytes in a human whole blood model.Infect,Immun,2000,68(7):39-41
[44]舒强，方学明,Stueber,F．手术后严重感染患者肿瘤坏死因子基因微卫星多态性及其与预后关系的研究．中华医学杂志,2000,80：193-195．
[45] Fang X M,Schroder S,Hoete A,et al.Comarison of two polymorphisms of the interleukin-1 gene family:inteleukin-l receptor antogonise polymorphism contributes to susceptibility to seuere sepsis.Crit Care Med,1999,27(7):1330-1334. [46] Stuber F,Petersen M,Bokelmanmm,F,et al.A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentratio ns ant outcome of patients with severe sepsis,Cris Care Med, 1996,24:38-42.
[47] Wright SD,Ramso RA,Tobias PS,et al.CD14,a receptor fou complexes of lipopo lysaccharides(LPS) and LPS binding protein.Science,1990,249(4975):1431
[48] Pugin,J,Heumann ID,Tomasz A,et al.CD14 is a pattern recognition receptor. Immunity,1994,1(6):509-516.
[49] Devitt A,Moffatt OD,Raykundalia C,et al.Human CO14 mediates recognition an d phagocytois of apoptotic cells.Nature,1998,392(6675):505-509.
[50] Yu B,Hailman E,Wright SD.Lipopolysaccharide binding protein and soluble CD14 catalyze exchange of Phospholipids J.Chin,Invest,1997(99)315-324.
[51] 张佃良.脓毒症的分子机制.国外医学，外科分册，2002(1):1-4.
[52] Leturcq DJ,Moriarty AM,Talbott G,et al.Antibodies against CD14 protect primat es from endotoxin-induced shock J Clin.Invest 1996,98:1533-1538.
[53] Kaisho T,Akira S.Pleiotropic function of Toll-like receptor.Microbes and Infecti on.2004,6(15):1388-1394.
[54] Philpott DJ,Girardin SE.The role of Toll-like receptors and Nod proteins in bac terial infection,Molecular.Immunology,2004,41(11): 1099-1108.
[55] Goldstein DR,Toll-like receptor and other links between immute and acquired a lloimmunity Current Opinion in Immunology,2004,16:538-544.
[56] 邓敏，陈晓飞.Toll样受体与常见病原菌感染之间关系的研究进展.2005，17(5):598-600.
[57] Beulter B,Poltorak A.Sepsis and evolution of the innate immune response.Crit Care Med,2001,29(7Suppl):S2-6;discussion S6-7.
[58] American College of Chest Physicians/Society of Critical Care Medicine Conse nsus Conference;definitions for sepsis and organ failure and guidelines for the use o f innovative therapies in sepsis.Crit Care Med,1992,20(6):864-874
[59] 姚咏明，柴家科，盛志勇.烧伤脓毒症的诊断标准与防治.中华烧伤杂志，2003，19(2):65-66
[60] Rivers E,Nguyen B,Havstad S,et al.Early goal-directed therapy in the treatment of severe sepsis and septic shock..N Engl J Med,2001,345:1368-1377
[61] Dellinger RP,Carlet JM,Masur H,et al.Surviving sepsis campaign guidelines for management of severe sepsis and septic shock.Crit Care Med,2004,32:858-873.
[62] Macarthur RD,Miller M, Albertson T,et al..Adequacy of early empiric antibiotictreatment and survival insevere sepsis:experience from the MONARCS trial. Clin In fect Dis,2004,38:284-288.
[63] Trautmann M,Zick R,Rukavina T,et al.Antibiotic-induced release of endotoxin:in vitro comparison of meropenem and other antibiotics.J Antimicrob Chemother,1998, 41(2):163
[64] Mattie H,Stuertz K,Nau R,et al.Pharmacodynarmics of antibiotics with respect to bacterial killing of and release of lipoteichoic acid by Streptococcus pneumoniac.J Antimicrob Chemother,2005,56(1): 154-159.[65 ] Reuben AD,Appelboam AV,Higginson I,et al.Earlay goal-directed therapy:a UK perspective.Emerg Med J,2006,23(11):828-832.
[66]Taylor RW,Manganaro L,O' Brien J,et al.Impact of allogenic packed red blood cell transfusion on nosocomial infection rates in critically ill patient.Crit Care Med,2 002,302249-2254.
[67] Cowin HL,Gettinger A,Pearl R,et al.Efficacy of recombinant human erythropoiet in in critically ill patients.JAMA,2002,288:2827-2835.
[68] Herbert PC,Wells G,Blajchman MA,et al.A multicentre randomized controlled clinical trial of transfusion requirements in critical care.N Engl J Med,1999,340(6):409 -417.
[69] Bernard GR,Wheeler AP,Russell JA.et al.Effects of ibuprofen on the physiology and survival of patients with sepsis.N Engl J Med,1997,336:912.
[70] Balk RA.Severe sepsis and septic shock:definitions ,epidemiology,and clinical manifestations.Crit Care Clin,2000,16:179-192.
[71] Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome.The Acute Respiratory Distress Syndrome Network.N Engl J Med,2000,3442(18):1301-1308
[72] Shenker Y,Skatrud JB.Adrenal insufficiency in critically ill patients.Am J Respir Crit Care Med,2001,163(7): 1520-1523.
[73] Bernard GR,Vincent JL,Laterre PF,et al.Efficacy and safety of recombirtant human activated protein C for severe sepsis.N Engl J Med,2001,344(10):699-709.
[74] Annane D,Sebille V,Charpentier C,et al.Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock.JAMA,2002,288(7):862-871
[75]刘超乾，盛湲。脓毒症治疗的新进展．国际外科学杂志．2007，34(12)：853—856．
[76] Hanrahian AH,Oseni TS,Arafah BM.Measurements of serum free Cortisol in crit ically ill patients.N Engl J Med,2004,350(16): 1629-1638.
[77] Vincent JL,Angus DC,Artigas A,et al.Effects of drotrecogin alfa(activated) on organ dysfunction in the PROWESS trial.Crit Care Med,2003,31(3)834-840.
[78] Abraham E ,Laterre PF,Gaeg G,et al.Drotrecogin alfa(activated) for adults with severe sepsis and a low risk of death.N Engl J Med,2005,353(3):1332-1341
[79] Ely EW,Laterre PF,Angus DC,et al.Drotrecogin alfa (activated) administration scross clinically important subgroups of patients with severe sepsis.Crit Care Med,2003,31(3):968-969.
[80] De Jonge E,Schultz MJ,Spanjaard L,et al.Effects of selective decontamination of digestive tract on mortality and acquisition ofresistant bacteria in intensive care:a randomized controlled trial.Lancet,2003,362(9389)1011-1016.
[81] Gao F,Gao E,Yue TL,et al.Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemia-reperfusion:the roles of P13-kinase,Akt,and endothelial nitric oxide synthase phosphorylation .Circulation,2002,105(12):1497-1502.
[82] Van den Berghe G,Wouters P,Weekers F,et al.Intensive insulin therapy in critically ill patients .N Engl J Med,2001,345(19):1361-1367.
[83] Van den Berghe G,Wouters P,Bouillon R,et al.Outcome benefit of intensive insulin therapy in the critically ill: Insulin dose versus lycaemic control. Crit Care Med,2003,31(2):359-366.
[84]兰海涛，刘清泉．脓毒症的中医理论探讨．中华中医药学会急诊分会第二届换届选举暨学术研讨会论文集，151—154.
[85]刘清泉，蓝海涛．中医对脓毒症的认识及辨证体系的研究．中华中西医临床杂志．2004,4(3)261-264．
[86]郭仁．《伤寒论》六经病变本质探讨．山东中医杂志,2005,9,24(9)：521-523．
[87]李彩月，李成福，等．中医外感热病对感染性全身炎症反应综合症的认识．中国中西结合急救杂志．2002,9(2)：63-64．
[88]王今达，李志军，李银平。从“三证三法“辨证论治脓毒症．中国危重病急救医学．2006,18(11)：643—645．
[89]刘清泉．对脓毒症中医病机特点及治法的认识．北京中医,2007,26(4)：198-200．
[90]姜树民，王哲．中医药通报,2007,6(4)：30-32．
[91]夏燕亮，刘昕．丹参对大鼠脓毒症急性肺损伤发生中TNF-Ad影响及对肺的保护作用。中药药理与临床,2004：20(6)15—17．
[92]黄琰．脓毒症发病状况及症候特点的临床研究．北京中医药大学硕士论文．
[93]魏利召，郑江，蒋栋能．赤芍拮抗内毒素活性的实验研究．中国临床药理学与治疗学，2005,10(3)：326-328．
[94]张艺平，韩鹏冲药抗内毒素研究进展．中国中西医结合急救杂志,2001，8(2)：122—124．
[95]戴锡珍，高淑娟．黄连解毒汤体外抗内毒素作用的实验研究．中国中医基础理论医学杂志,2000,6(5)：31-32．
[96]曹书华，高红梅,王永强．“神农33号”对多器官功能障碍综合征大鼠细胞因子的影响．中哈急诊医学杂志,2003,12(2)：94-96．
[97]郭昌星，杨兴易，林兆奋，等．血府逐瘀汤对全身炎症反应综合征患者血氧自由基的影响．中国中西医结合急救杂志,2002,9(12)：720-722．
[98]王文俊，吴咸中．化解冲剂对脓毒症大鼠神经肽及细胞因子的调节作用．中国免疫学杂志，1997,1 3(2)：84-86．
[99]陈海龙，吴咸中，关风林，等．中医通里攻下法对多器官功能不全综合征时肠道屏障功能保护作用的实验研究．中国中西医结合杂志,2000,20(2)：12．
[100]姚睿智，谢晓华，陈铭．通腑泻热灌肠剂对急腹症脓毒症术后血清C反应蛋白的影响-广州中医药大学学报,2002,19(2)：96-98． ．
[101]万幸，刘倩娴,王培训．大承气汤对全身炎症反应干预作用的实验研究．广州中医药大学学报,2003,20(2)：153-156．
[102]于泳浩，崔乃强，傅强，等．大承气汤颗粒对重型脓毒症促炎-抗炎反应平衡的影响。中国中西医结合外科杂志,2004,10(6)：409-412．
[103]曹书华，王今达．大承气汤在多器官功能障碍综合征治疗过程中的免疫调节作用。中华创伤杂志,2004,20(12)720-723
[104]李军茹．大柴胡汤加味治疗多器官功能失常综合征及对血浆内毒素影响的观察。浙江中医杂志,2005,6：264-265．
[105]李蓉，程建详。参麦注射液对盲肠结扎并穿孔致脓毒症大鼠的免疫调节作用。现代中西医结合杂志,2004,13(16)：2135-2136．
[106]靳桂贞，潘雪。解热硝烟胶囊的药理作用初探．中药通报，1987,12(1)：2
[107]叶祖光,王金华，王跃生，等．安宫牛黄丸及其简化方的药效学研究．中国中药杂志．2003,28(7)：636．
[108]蒋玉凤，黄启福，严京，等．清开灵对加图内毒素性发热和脑脊液cAMP含量的影响．北京中医药大学学报，1994,17(5)：66．
[109]韦文哲，吴树勋，张建树，等．牛黄醒脑注射液药理作用的初步研究．中成药研究，1981，(6)：32．
[110]朱培纯，等．清开灵注射液对大白鼠脑内蓝斑乙酰胆碱酯酶及单胺氧化酶的影响。中成药研究．1981；(3)：33．
[111]朱承喜，侯家玉，金恩波，等．安宫牛黄丸及清开灵注射液对实验性氨昏迷动物皮层电图的影响．中西医结合杂志，1989,9(12)：739．
[112]．刘涛，沈凤阁，王灿，等．安宫牛黄丸对兔脑脊液乳酸脱氢酶、脑组织化学乳酸脱氢酶的影响．江苏中医，1987,(6)：33
[113]黄玉芳，邓郗年，何原惠，等．安宫牛黄丸对脑水肿家兔脑内酶的影响．南京中医学院学报，1991，7(2)：92．
[114]白丽敏，孙红梅，朱培纯．等．清开灵注射液对实验性脑出血大鼠闹内P物质的影响，北京中医药大学学报，1996,19(6)：67．
[115]何原惠，黄玉芳，郑郗年，等．安宫牛黄丸对实验性脑水肿动物肝脏的影响．江苏中医，1992,(12)：38．
[116]叶百宽，贲长恩，俞慧珠，等．清开灵对实验性肝损伤修复作用的组织学和组织化学的探讨，中华内科杂志，1981,20(1)：38．
[117]傅志慧．安宫牛黄丸治疗脑卒中急性期神昏的临床观察．新中医，1993,25(12)：33．
[118]于风云，李秀梅，孙莹．等．安宫牛黄丸灌肠治疗中风病人53例临床报告。中医药信息，1993,(2)：33．
[119]邢峰丽，李青，张伟，等．安宫牛黄丸治疗脑中风34例临床观察．河北中医,2005,27(1)：13-14．
[120]李向荣，李小文．安宫牛黄丸治疗蛛网膜下腔出血后脑血管痉挛疗效观察．中国中西医结合急救杂志，19966(10)：479-480．
[121]高大硕，刘本春．安宫牛黄丸治疗颅脑损伤术后高热昏迷20例．中西医结合实用临床急救，1997,4(11)：498．
[122]傅朗林。安宫牛黄丸治疗肺性脑病15例．中西医结合实用临床急救．1996,3(12)556．
[123]熊曼琪，彭万年。安宫牛黄丸治验五则．中国医药学报．1988,(4)：44．
[124]虞坚尔，邱根详，李晓葵．等．安宫牛黄丸在儿科临床的再运用．上海中医药杂志，1994,5：18—19。
[125]张文辉，清开灵注射液治疗上呼吸道感染临床疗效观察．河南医药信息,2001，9(18)39-40.
[126]陈峰霖。安宫牛黄丸治疗顽固性癌性高热的疗效观察．实用中西医结合杂志．1994，7(9)：545．
[127]黄金平。安宫牛黄丸治疗农药中毒．浙江中医杂志，1985,20(8)：376．
[128]王肖蓉，孙荣智．安宫牛黄丸治疗败血症的体会．河南医药信息,2002,10(11)：6．
[129]匡耀祖．以安宫牛黄丸为主治疗黄疸型肝炎．江西中医药，1988,(6)：17．
[130]闫吉文．清开灵配伍胃苓汤治疗急性黄疸型肝炎疗效观察．黑龙江中医药，1991，(3)：34
[131]于新芳,王丽娟．病毒唑和安宫牛黄丸治疗流行性乙型脑炎疗效观察．中西医结合实用临床急救．1996,3(10)：452．
[132]贾印宝．安宫牛黄丸治疗流行性出血热．中成药，1993,(6)：44．
[133]王春英，丁汉和，李作平．安宫牛黄丸治疗流行性出血热的初步观察．临沂医专学报．1993,15：100．
[134]李爽．清开灵的药理作用与临床应用。现代中西医结合杂志,2009,18(1)：108-110．
[135]王永恒．安宫牛黄丸在颅脑损伤中对意识障碍恢复的疗效观察．中西医结合杂志．1989，9(12)：726．
[136]周杰，徐蔚，董涛，等．中西医结合治疗重型颅脑损伤68例．中国煤炭工业医学杂志．2006,9(10)：1099．
[137]潘华新，王培训，王宁生．安宫牛黄丸及其类方临床应用概况．新中医,2001,33(12)：64-66．
[138]史宇辉．肿瘤坏死因子研究进展。河北医科大学学报，1998,19(4)：249-252．
[139]Spriggs DR,Zaheer T,Zhong W,et al.Tumor necrosis factor and interleukin-6 mRNA expression in neonatal Lewvis rat Schwann cells.Marcel Dekker Ink, 1991,72(1):33-34.
[140] Hamish R.Michie MB,Kirk RM,et al.Detection of circulation tumor necrosis factor after endotoxin administration.New Eng J Med, 1988,318(2): 1841.
[141] Wang H,Bloom O,Zhang M,et al.HMG-1 as a late mediator of endotoxin lethality in mice.Science,1999,285(5425):248-251.
[142]梁晋川．高迁移率族蛋白1的研究进展。医学综述,2006,12(11)：653—656．
[143]Wang H,Yang H,Tracey KJ.Extracellular role of HMGB1 in inflammation and sepsis.J Intern Med,2004,255(3):320-331.
[1]陈德昌,李红江,乔林,等.大黄对创伤后脓毒症大鼠肝细胞线粒体功能的影响(J),中国中西医结合急救杂志,2002；9(1)；911.
[2]沈恬.大黄对家兔内毒素发热及血浆cAMP和cGMP含量的影响(J),上海中医药杂志,1991；5(2)；46.
[3]余林中,吴锐,黄泳,等.凉膈散对家兔内毒素温病模型的解毒作用研究(J).中药药理与临床,1996；(5)；46
[4]耿耘,马超英,肖诚,等.牛珀至宝丹对内毒素休克大鼠血液流变的影响(J),中国危重病急救医学,1997；9(12)；715
[5]Wichman KA,Bauce AE,Chaudry IH,et al.Sepsis and septic shock:A review of 1 aboratory models and a proposal.J Surg Res,1980,29:189
[6]金惠铭.盲肠结扎穿刺后的大鼠败血症模型.中国病理生理学杂志.1990,6(2)：126-127.
[7]Simon R,Wetzel N,Winsey K,et al.Supplemental dietary tyrosine in sepsis and ac ute hemorrhagic shock.Arch Surg,1987,122:78.
[8]王肖蓉,孙荣智.安宫牛黄丸治疗败血症的体会.河南医药信息,2002,10(11)：6.
[9]Bone RC Sprung CL,Sibbald WJ.Definitions for sepsis and organ failure.Crit Ca re Med,1992,20,724-726.
[10]Levy MM,Fink MP,Marshall JC,et al.2001 SCCM/ESICM/ACCP/ATS/SIS intern ational Sepsis Ddfinitions Conference Crit Care Med,2003;31;1250-1256.
[11]American College of Chest Physicians/Society of Critical Care Medicine Conse nsus Conference;definitions for sepsis and organ failure and guidelines for the use o f innovative therapies in sepsis.Crit Care Med,1992,20(6):864-874.
[12]Tracey KJ,Cerami A.Tumor necrosis factor,other cytokine and disease.Annu Rev Cell Biol1993,9:317-343.
[13]Tracey KJ,Beutler B,Lowry SF,et al.Shock and tissue injury induced by recomb inant human cachectin. Science,1986,234:470-474.
[14]Bone RC.The pathogenesis of sepsis.Ann Intern Med,1991,115:457-469.
[15]Nathan CF.Sectrtory products of macrophages.J Clin Invest,1987,79:318-326.
[16]Wang H,Tracey KJ.Tumor necrosis factor,interleukin-6,macrophage migration inh ibitory factor,and macrophage inflammatory protein-1 in inflammation,In Gallin JI,Sn yderman R(ed)Inflammation:Basic Principle and Clinical Correlates.3rd Edition Philade lphia:Lippincott,Williams and Wilkins,1999:417-485.
[17]陈奇.中药药理研究方法学.,第2版.北京：人民卫生出版,2006,832.
[18]王同明,李玉玲,等.胆色素代谢与黄疸.生物化学与检验技术.江苏科学技术出版社,1995.
[19]王明海,张义胜,赵国海.等.实验性大鼠重症急性胰腺炎早期肺组织中MDA／MPO的变化〖J〗.皖南医学院学报,2006,25(2)：81-83.
[20]王世锋,王文波,朱嘉.高压氧暴露对小鼠肺组织匀浆髓过氧化物酶活性的影响〖J〗.海军医学杂志,2005,26(2)：102-103.
[21]HIROYUKI Y,ALEX B,WILLIAM G,et al.Enhanced pulmonary expression of CXC chemokines during hepatic ischemia/reperfusion-induced lung injury in mice.J S ur Res,1999,81(1):33-37.
[22]张佃良,黎介寿,江志伟.脓毒症的分子机制.国外医学外科学分册,2002,29(1)1-3.
[23]杨英详.脂多糖结合蛋白在脓毒症中的作用及临床意义〖J〗.国外医学外科学分册,1999,26(3)：131-134.
[24]Heithan TH,Bruce CK,Dabid WM,et al.Post-injury multiple organ failure;the rol e of the gut,Shock,2001,15:1.
[25]Karima R,Matsumoto S,Higashi H,et al.The molecular pathogenesis of endotoxi c shock and organ failure.Molecular Med Today,1993,3:123.
[26]任成山.脓毒症的发病机制(J)。Chin J Care Med.Oct.2005,Vol 25,No.10
[27]F.M.奥斯伯,R.布伦特,R.E.金斯顿,等.精编分子生物学实验指南,第五版.北京：科学出版社,2008.
[28]杨丽萍,姚咏明,盛志勇.脓毒症发病的炎症反应与免疫紊乱机制.感染、炎症、修复,2008,9(1)：48-51.
[29]Hamish R.Michie MB,Kirk RM,et al.Detection of circulation tumor necrosis fac tor after endotoxin administration.New Eng J Med,1988,318(2):1841.
[30]Matsukawa A,Kaplan MH,Hogaboam CM,et al.Pivotal role of signal transducera ndactivator of transcription STAT4 and STAT6 in the innate immune response durin g sepsis (J).J Exp Med,2001;193(6);679-688.
[31]Riley JK,Takeda K,Akira S, et al.Interleukin 10 receptor signaling through the JAK/STAT pathway (J).J Biol Chem,1999;274(23); 16513-16521
[32]Reddy J,Chastagner p,Fiette L,et al.IL-2 induced tumornecrosis factor beta expr ession,Further analysis in the IL-2 knockout model,and comparison with TNF alpha,l ymphotoxin beta.TNFR1 and TNFR2 modulation(J).Intmmunology,2001;13(2);137-147
[33]Wang H,Bloom O,Zhang M,et al.HMG-1 as a late mediator of endotoxin lethal ity in mice.SCIENCE,1999,285:248-251
[34]Wang H,Yang H,Tracey KJ.Extracellular role of HMGB1 in inflammation and sepsis,Intern Med,2004,255:320:331.
[35]Andersson U,Wang H,Palmblad K,et al.High mobility group 1 protein stimulate s proinflammatory cytokine synthesis in human monocytes.J Exp Med,2000,192(4): 565-570.
[36]Yang H,Ochani M,Li J,et al.Reversing established sepsis with antagonists of en dogenous high mobility group box 1.Proc Natl Acad Sci USA.2004,101:296-301.
[37]Venkataraman R,Kellum JA,Song M,et al.Resuscitation with Ringer's ethylpyruv ate solution prolongs survival and modulates plasma cytokine and nitrite/nitrate conc entrations in a rat model of lipopllysaccharide induced shock.Shock,2002,18:507-512
[38]方文慧,姚咏明,施志国,等.严重烫伤后高迁移率族蛋白-1基因表达的改变及意义.中华外科杂志,2001,39：137-140.
[39]李红云,姚咏明,施志国,等.高迁移率族-1蛋白在烫伤后金黄色葡萄球菌脓毒症中的的改变与意义.中华实验外科杂志,2001,18：336-338.
[40]Quimby F,Nguyen HT.et al.Aninmal studies of toxic shock syndrome CRC Crit Rev Microbiol,1985,12:1-44.
[41]Shiranee S,Cohen J.Gram-positive sepsis:Mechanisms and differences from gram-negative sepsis.Infect Dis Clin Nor Am,1999,13:397-412.
[42]王松柏.Janus激酶／信号转导和转录激活因子途径与脓毒症的研究进展,中国危重急救医学,2003,15(11)：690
[43]姚咏明,盛志勇,脓毒症信号转导机制的现代认识,中国危重病急救医学,2003,15(1)：3
[44]Mada K,Leonard W J.The JAK/STAT pathway(J)Mol Immunol,2000;37(1);1
[45]Miscia S,Marchisio M,Grili A,et al.Tumor necrosis factor alpha (TNF-activates) JAK1/STAT3-STAT5 B signaling through TNF R-1 in human B cells.Cell Growth Differ,200213(1):13.
[46]Riley J K,Takeda K,Akira S,et al;Interleukin-10 receptor signaling through the JAK/STAT pathway(J).J Biol Chem; 1999,274(23);16513.
[47]Andrejko K M,Chen J,Deutschman C S.Intrahepatic STAT-3 activation and acut e phase gene expression predict outcome after CLP sepsis in the rat (J).Am J Physi ol,1998;275;G1423
[48]Jacobs AT.Ignarro L J.Lipopolysac-charide-induced expression of interferon-beta mediates the timing of inducible nitric-oxide synthase induction in RAW264.7 macro phages(J) J Biol Chem,2001;76(51);47950.
[49]Arrero M B,Venema V J,He H,et al,Inhibition by the JAK/STAT pathway of I FN gamma-and LPS-stimulated nitric oxide synthase induction in vascular smooth m uscle cells(J) Biochem Biophys Res Commun,1998;252(2);508.
[50]姚胜,姚咏明,李红云,等.烫伤脓毒症大鼠肝／肺组织STAT活化规律及意义(J)解放军医学杂志,2002；27(9)：763.
[51]Benkhart E M,Siedlar M,Wedel A,et al.Role of STAT3 in lipopolysac-charide-induced IL-10 gene expression (J) J Immunol,2000;165(3);1612
[52]Matsukawa A,Kaplan MH,Hogaboam CM,et al.Pivotal role of signal transducer and activator of transcription STAT4 and STAT6 in the innate immune response dur ing sepsis (J).J Exp Med,2001;193(6);679-688
[53]Streetz K L;Wustefeld;Klein C;et al.Mediators of inflammation and acute phase response in the liver.Cell-Mol-Biol,2001;47(4):661-673.
[54]王松柏,姚咏明,董宁,等.JAK／STAT通路介导脓毒症大鼠肝组织高迁移率族蛋白B1 mRNA表达的研究.中国危重病急救医学,2003,15：147-149.
[55]林洪远,脓毒症——挑战与对策,中国危重病急救医学,2004；16(6)；325-356
[56]Heithan TH,Bruce CK,Dabid WM,et al.Post-injury multiple organ failure;the rol e of the gut,Shock,2001;15;1
[57]Parima R,Matsumoto S,Higashi H,et al.The molecular pathogenesis of endotoxic shock and organ failure.Molecular Med Today,1993;3;123
[58]Jarrar D,Chaudry IH,Wang P.Organ Dysfunction following hemorrhage and seps is;Mechanisms and therapeutic approaches.Intl J MOL Med,1999;4;575.
[59]Huber TS,Gaines GC,Welborn B,et al.Anticytokine therapies for acute inflamma tion and the systemic inflammatory response syndrome:IL-10 and ischemia/reperfusio n injury as a new paradigm.Shock.2000;13;434-452.
[60]Dell Albani P,Santongelo R,Torrsi L,et al.JAK/STAT signaling pathway mediat es cytokine-induced iNOS expression in primary as troglial cell culture.J Neurosci R es,2001;65;417-424.
[61]姚咏明,盛志勇,脓毒症信号转导机制的现代认识,中国危重病急救医学,2003：15(1)：3-6.
[62]BenkhartEM,SiediarM.WedeLA,etal,Roleof STAT3 inlipopolysac-charideinduced I L-10 genne expression (J)Jimmunol,2000,165(3):1612-1617.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |